The genomic DNA profiles of prostate cancers with aggressive features were compared to the profiles of matched normal DNA to identify genes that are selectively amplified in the cancer cells. One of the identified genes, MCM7, which is a component of the DNA replication licensing complex, has been studied extensively both at the DNA and protein levels in human prostate tissues. Approximately half of the prostate cancer specimens studied showed MCM7 gene amplification, and 60% of the aggressive prostate cancer specimens had increased MCM7 protein expression. Amplification or overexpression of MCM7 was significantly associated with relapse, local invasion and a worse tumor grade. Constitutive expression of MCM7 in a human prostate cancer cell line, DU145, resulted in markedly increased DNA synthesis and cell proliferation compared to vector-only controls, and an increased cell invasion in vitro. Indeed, MCM7 overexpression produced primary tumors 12 times larger than vector-only controls and resulted in a rapid demise of mice bearing those tumors. These studies implicate MCM7, and the DNA replication licensing gene family, in prostate cancer progression, growth and invasion.
Introduction
At the current rates of diagnosis in the United States, one man in six will be diagnosed with prostate cancer during his lifetime; prostate cancer is second only to cutaneous cancer in frequency. For about 30 000 men per year, the disease transforms from a relatively indolent condition to a lethal one (Jemal et al., 2005) .
Despite the widespread prevalence of prostate cancer, the molecular events underlying prostate carcinogenesis, disease progression and emergence of the lethal, androgen refractory disease remain unclear. A better understanding of the genetic aberrations in prostate cancer is fundamental to the identification of new etiologic, prognostic or therapeutic targets.
There are many alterations in the gene expression of malignant prostate tissues relative to benign specimens. These changes provide a rudimentary basis from which prostate tumors can be classified (Luo and Yu, 2003) . Patterns of gene expression can distinguish aggressive, metastatic or lethal tumors from more indolent prostate cancer, but in the absence of an established genetic fingerprint, the disease is still defined based on clinical criteria. Identifying and characterizing those genes that are uniquely expressed in the late-stage disease may provide clues about the mechanisms of disease progression. In this regard, the most promising aspect of gene array analyses has been the identification and characterization of single gene, providing new insight into the biology of the disease.
In this report, we employed an array analysis technique that was developed to quantify DNA copies of individual genes. This analysis identified the gene MCM7, which was dramatically amplified in aggressive prostate cancer. MCM7 is a critical component of the DNA replication licensing complex, with a key role in controlling the initiation of DNA replication (Lu et al., 1999; Labib et al., 2001; Blow and Hodgson, 2002; Edwards et al., 2002) . Fully differentiated cells are virtually depleted of replication complex proteins. Based on the general hypothesis that amplification of any gene in aggressive prostate cancer may provide insights into the biology of that form of the disease, the specific expression and function of MCM7 in prostate cancer was evaluated. Multiple lines of evidence suggest that MCM7 amplification and increased expression characterize and contribute to the aggressive phenotype of prostate cancer.
Results
Genomic DNA array analyses of two cases of primary prostate cancers with aggressive features were compared to analyses from matched peripheral nucleated blood cells using the same template (Affymetrix u95av2 chips). In all, 92 genes and expressed sequenced tags (ESTs) consistently had a twofold or greater number of genome copies in the prostate cancer specimens relative to matched blood cells (Po0.01, using baseline analysis by Microarray Suite 5.0t). To determine whether these gene amplifications were associated with increased expression of the same loci, mRNA expression arrays were performed with the same tumor samples and matched normal prostate tissue adjacent to but separate from the tumor. Only five of the 92 potential amplifications had increased mRNA expression. Using SYBRgreen quantitative PCR and fluorescence in situ hybridization (FISH) with bacterial artificial chromosome (BAC) containing these genes, we confirmed that two of these genes were amplified in the prostate cancer specimens. One of these genes, MCM7, located at 7q21.3 and a component of DNA replication licensing complex, was found to be amplified four-and 15-fold, respectively.
MCM7 gene DNA copy is increased in a subset of prostate cancers To determine the prevalence of MCM7 amplification in prostate cancer, FISH analyses were performed on 74 prostate samples, including 58 cancers and 16 benign tissues (Figure 1a ). Nearly half, (26/58, 45%) of the prostate cancers had at least a doubling in the number of genome copies (compared to the centromere of chromosome 7) (Table 1) . Meanwhile, none of the benign prostate tissues demonstrated a similar amplification. As further validation of these findings, SYBR-green quantitative PCR was performed on an additional 133 prostate samples, including 119 cancers and 14 normal tissues. In this analysis, 50% (59/119) of the prostate Amplification of MCM7 in prostate cancer B Ren et al cancers had at least a two-fold increase in the MCM7/bactin ratio relative to DNA from benign prostate specimens. In the most upregulated case, the MCM7/ b-actin ratio in the cancer sample was 16-fold greater than control levels. These data support the hypothesis that MCM7 is amplified in prostate cancer.
To examine whether MCM7 amplification is associated with a particular disease phenotype, the analysed prostate cancers were classified according to disease progression. Aggressive tumors were defined as either (i) distant metastasis at the time of surgery or within 5 years postoperatively, or (ii) biochemical (prostatespecific antigen (PSA)) failure within 5 years of surgery and compared to those lacking either objective metastases or positive biochemical test results. Cancer samples with less than 5 years of follow-up were considered to be indeterminate. By both FISH and quantitative PCR, MCM7 copy number was significantly higher in the aggressive prostate cancers (Figure 1b , Table 1 ) with an average of 3.1 copies of MCM7 genes per centromere (by FISH) and six copies per b-actin (by PCR) compared to 2.3 and 1.7 in nonaggressive tumors, respectively.
MCM7 protein expression is increased in prostate cancer
To evaluate whether MCM7 protein expression is also increased in prostate cancer, immunohistochemistry for MCM7 was performed in 501 prostate tissues, including 181 benign tissues and 320 cancers, obtained from 260 individuals. Of the 320 prostate cancer tissues examined, 227 had at least 5 years of clinical follow-up, and the remaining samples were considered indeterminate due to lack of follow-up information (see Table 2 for details).
In benign prostate tissues, MCM7 expression was detected only focally in the basal cell layer. MCM7 labeling was negligible in acinar epithelial cells (for scoring criteria, see Materials and methods). None of the normal prostate tissues received a score more than weakly positive (1 þ ) (Figure 1c and d) . Consistent with the amplification data, the majority (62/101, 61.4%) of aggressive prostate cancers received scores of 2 þ or above, while a minority (18/126, 14.3%) of the nonaggressive prostate cancers had that level of expression. Interestingly, among the prostate cancers with increased MCM7 copy number, the majority (69/83, 83%) had high protein expression (2 þ or more), Increased MCM7 protein expression (X2 þ ) was twice as likely to be associated with local tumor invasion (pT3a or above) than tumors without increased MCM7 expression, 26/64 (40.6%) vs 36/256 (14.1%), respectively (Po0.002, rank-sum). Not surprisingly, tumors with increased MCM7 protein expression were more poorly differentiated: 43.5% of samples with a Gleason score X8 had increased MCM7 expression, while only 30% of the samples with lower scores showed increased MCM7 expression (Po0.04).
MCM7 amplification and protein expression are associated with prostate cancer relapse Amplification of MCM7 was associated with a significantly increased rate of prostate cancer relapse within 5 years of radical prostatectomy (defined as a detectable PSA): 76.5% (52/68) patients with MCM7 amplification relapsed compared to only 12.3% (7/57) of patients without MCM7 amplification (Po0.0001, logrank test) ( Figure 2a , Table 3 ). Similar results were seen with MCM7 protein expression: 76.3% patients with X2 þ MCM7 expression experienced a recurrence within 5 years after radical prostatectomy compared with only 26.5% patients with weak MCM7 expression (Po0.006) ( Figure 2b , Table 3 ). The combination of MCM7 amplification and overexpression generated additional improvement in separating the two groups ( Figure 2c , Table 3 ).
MCM7 overexpression increases DNA synthesis, cell proliferation in vitro, and metastases and mortality in vivo In all, 11 clones of DU145 transfected with a constitutive MCM7 cDNA overexpression vector were (Table 4 ) compared to vector-only controls. In vivo, DU145 pCMV-MCM7 xenograft tumors were 12 times larger than vector-only control tumors, 2.58 vs 0.22 cm 3 , respectively (Table 5, Po0.0001), with a 50% mortality within 6 weeks of inoculation (Figure 3d , P ¼ 0.0063). These findings are consistent with the clinical findings that increased MCM7 expression is associated with higher rates of local tumor invasion.
Discussion
Many genomic abnormalities have been identified in various subsets of prostate cancer (Luo and Yu, 2003 ), yet few genes have been associated with the progression of prostate cancer. Currently, several methodologies are used to define alterations in the prostate cancer genome. The single-nucleotide polymorphism chip (SNP chip) is used to identify qualitative differences between samples (Dumur et al., 2003) . Comparative genomic hybridization using BAC clones in an array has been popular and successful for quantitative analysis (Wolter et al., 2002; Paris et al., 2003) . However, the size of each clone is large with BAC studies, and the method does not provide single gene resolution. cDNA genome array is promising (Clark et al., 2003) . In this report, we developed a gene-specific genome array analysis utilizing the template of the Affymetrix u95av2 chip for quantifying DNA copy number of individual genes. This array analysis has several distinct advantages over the other genome arrays. Firstly, there are a large number of genes in a single array. Secondly, there are multiple oligonucleotide representations of a single gene, which enables statistical analysis to rule out falsepositive results. In addition, the hybridization cocktail can be retrieved for repeat hybridization if necessary. And finally, it is easy to test whether the findings correlate with RNA expression data.
MCM7 is an essential component of the replication fork required for DNA synthesis (Romanowski et al., 1996; Ishimi, 1997) . MCM7 and several other components bind to the genome replication origins and allow the DNA polymerase complex to replicate DNA (Aparicio et al., 1997; Pacek and Walter, 2004) . The expression of these elements is tightly controlled by several signaling pathways to ensure proper DNA replication (Kukimoto et al., 1998; Fujita et al., 1999; Jiang et al., 1999; Pasion and Forsburg, 1999) . For example, expression of MCM7 is shut down during S, G 2 and early M phase to prevent reinitiation of DNA synthesis. Amplification of MCM7 may reduce the phase-specific control of its expression. The continuous presence of MCM7 throughout the cell cycle not only recruits more cells into the proliferation cycle but may also induce reinitiation of improper DNA synthesis, and thereby increase the risk of chromosome abnormalities (Clark et al., 2003) . The strong association of MCM7 amplification and protein expression with prostate cancer recurrence may provide clues about the potential role of dysfunctional DNA replication in determining tumor indolence or aggressiveness. Prospective studies of MCM7 expression are required to establish it as an independent prognostic factor in prostate cancer.
Increased expression of MCM7 and its family members has been reported in a variety of malignancies (Brake et al., 2003; Xue et al., 2003; Cromer et al., 2004; Padmanabhan et al., 2004) and MCM7-expressing cells have been demonstrated to produce a larger tumor volume in xenograft cancer models (Yoshida and Inoue, 2003) . However, none of these studies has provided evidence for a determinant role of MCM7 in the development of an aggressive clinical phenotype. A recent report suggested that MCM7 is a useful proliferation marker for prostate intraepithelial neoplasia and prostate cancer (Padmanabhan et al., 2004) , but did not link MCM7 with tumor biology. A gain of the 7q chromosomal region that includes MCM7 has been observed in some highly invasive prostate cancers (Laitinen et al., 2002) . To our knowledge, this is the first report showing strong associations between MCM7 amplification/expression and prostate cancer progression. Although increased DNA copy of the MCM7 gene in prostate cancer is the likely driving force in increasing the expression of this gene in prostate cancer, the in vivo data suggest that consistent expression of MCM7, in the absence of amplification, can substantially increase tumor growth rates and reduce survival. Thus, a combined genomic and protein expression analysis of MCM7 is probably the ideal way to analyse the relationship of alteration of MCM7 and prostate cancer. Taken together, these data implicate MCM7 in prostate cancer progression and recurrence, and suggest that MCM7 could be potentially used to predict clinical 
Materials and methods

Sample preparation
Fresh prostate cancer tissues, recovered immediately from the operating room after removal, were dissected and trimmed to obtain pure tumor (completely free of normal prostate acinar cells) tissues. Microdissection was coupled with sandwich frozen and permanent section analyses to confirm the purity and homogeneity of the samples: gross and microscopic analyses were performed by board-certified GU pathologists. For tumor tissues, samples with less than 10% of stromal components were selected for genome array analysis. Two cases used in the genome array hybridization were pathological stage IIIb at the time of radical prostatectomy, and these patients experienced metastasis within 6 months of surgery.
For FISH analysis, formalin-fixed paraffin-embedded tissues were used. FISH hybridization was performed on a 5-mm thin section of selected tissue blocks. In all, 74 samples including 58 tumors and 16 normal prostate tissues were used (Table 2 ). For SYBR-green quantitative PCR, tissues were obtained fresh within 30 min of surgical resection. These tissues were overlaid with OCT and snap frozen. Microdissections were performed on sections of frozen tissues. A total of 100 000-500 000 cells were obtained for each sample, depending on the size and dissectability of the samples. DNA was purified with QiaAmp DNA mini kit (Qiagen, Valencia, CA, USA). The procedure of DNA extraction followed the detailed manuals provided by the manufacturer. In total, 133 samples including 119 prostate cancer and 14 normal prostate samples were examined. For immunostaining, three tissue array slides and 40 thin sections of formalin-fixed paraffinembedded tissues were used. Tissue arrays of prostate tissues were constructed by arraying a total of 461 formalin-fixed paraffin-embedded tissue blocks using a 1-mm diameter array donor needle into three receiver paraffin blocks by a semiautomatic tissue arrayer (Chemicon, San Diego, CA, USA). Each block contains 150 to 160 tissue cores. Thin sections 3 (3 mm) of tissue array blocks were made for immunostaining assays. In total, 154 prostate cancer samples were assayed for both immunostaining with anti-MCM7 antibody and genome analysis. In all, 17 prostate cancer and 10 normal prostate samples were assayed with both FISH and SYBR-green quantitative PCR. The clinical and pathological information about the prostate cancer samples for validation purposes are provided in Table 1 . The procedure of archivedtissue collection, annonimization and experimental protocols were approved by institutional review board.
Oligonucleotide genome hybridization
Genomic DNA (1 mg) was digested with Tsp509I. The DNA fragments were purified and ligated with T7-adaptor oligonucleotides (GGCCAGTGAATTGTAATACGACTCACTATA GGGAGGCGG/AATTCCGCCTCCCTAAGTGAGTC). The ligated DNA was subsequently filled in with T4 polymerase to produce blunt-ended DNA fragments. The DNA was extracted using QiaAmp DNA mini kit (Cat#51304, Qiagen, Valencia, CA, USA). The extraction procedure followed the detail manuals provided by the manufacturer. The purified DNA was then incubated at 371C for 4 h in an in vitro transcription reaction to produce biotin-labeled RNA probes with the MEGAscriptt system (Ambion Inc., Austin, TX, USA). RNA (40 mg) were fragmented by incubation in a buffer containing 200 mM Tris-acetate, pH 8.1, 500 mM KOAc, 150 mM MgOAc at 951C for 35 min. The fragmented RNA was then hybridized with a pre-equilibrated Affymetrix chip (u95av2) at 451C for 14-16 h. After hybridization, cocktails were removed, the chips were then washed in a fluidic station with a low-stringency buffer (6 Â SSPE, 0.01% Tween-20, 0.005% antifoam) for 10 cycles (two mixes/cycle) and a stringent buffer (100 mM MES, 0.1 M NaCl and 0.01% Tween-20) for four cycles (15 mixes/cycle), and stained with SAPE (Strepto-avidin Phycoerythrin). This was followed by incubation with biotinylated mouse anti-avidin antibody, and restained with SAPE. The chips were scanned in an HP ChipScanner (Affymetrix Inc., Santa Clara, CA, USA) to detect hybridization signals. Hybridization data were normalized to an average target intensity of 500/chip. Subsequently, mRNA microarray analysis Total RNA was extracted and purified with Qiagen RNeasy kit (Qiagen, Valencia, CA, USA). Total RNA (5 mg) were used in the first-strand cDNA synthesis with T7-d(T) 24 primer (GGCCAGTGAATTGTAATACGACTCACTATAGG-GAGGCGG-(dT) 24 ) by Superscriptt II (GIBCO-BRL, Rockville, MD, USA). The second-strand cDNA synthesis was carried out at 161C by adding Escherichia coli DNA ligase, E. coli DNA polymerase I and RnaseH in the reaction. This was followed by the addition of T4 DNA polymerase to the blunt ends of newly synthesized cDNA. The cDNA was purified through phenol/chloroform and ethanol precipitation. The purified cDNA were then incubated at 371C for 4 h in an in vitro transcription reaction to produce cRNA labeled with biotin using MEGAscriptt system (Ambion, Inc, Austin, TX, USA). cRNA (15-20 mg) were fragmented by incubating in a buffer containing 200 mM Tris-acetate, pH 8.1, 500 mM KOAc and 150 mM MgOAc at 951C for 35 min. The fragmented cRNA were then hybridized with a pre-equilibrated Affymetrix chip (u95av2) at 451C for 14-16 h. The oligo genechip (u95av2) wash, staining, scanning and signal analysis procedures were similar to those described in the above paragraph.
Fluorescence In Situ hybridization Tissue slides (5 mm) were placed in 2 Â SSC at 371C for 30 min. Slides were then removed and dehydrated in 70 and 85% ethanol for 2 min each at room temperature, and air-dried. The probe for FISH analysis was obtained through screening BAC three-level paneled library (InVitrogen, CA, USA) using two sets of primers specific for MCM7 exons (GGCCCTAGCAG CAACAAGCCT/TACCGGCTGGTAGGTCTCTGC and AAGTGTCCGGTTCTCTGAGG/CCTCATATTCATCCAG AGCC). The DNA from the selected clone was extracted using Nucleobond Ax kit (Macherey-Nagel, Easton, PA, USA). The probe was prepared by combining 7 ml of biotin-labeled genomic sequence containing MCM7 (150 Kb)/50% formamide with 1 ml of direct-labeled CEP7 Spectrum Orange (Vysis, Downers Grove, IL, USA). The probe was denatured for 5 min at 751C. Sections of formalin-fixed tissues were denatured in 70% formamide for 3 min, and dehydrated in 70, 85, and 100% ethanol for 2 min each at room temperature. The denatured probe was placed on the slide, cover-slipped, sealed with rubber cement, placed in a humidified chamber and hybridized overnight at 371C. Coverslips were removed and the slides were washed in 2 Â SSC/0.3% NP-40 at 721C for 2 min. Slides were then held in phosphate-buffered saline (PBS) at room temperature in the dark for 2 min. The biotin label was visualized by conjugation with avidin-FITC (Zymed, San Francisco, CA, USA), cover-slipped and incubation in a moist chamber in the dark at 371C for 20 min. Slides were washed three, times for 2 min each in fresh PBS. Slides were then airdried in the dark and counterstained with DAPI. Analysis was performed using a Nikon Optiphot-2 and Quips Genetic Workstation equipped with Chroma Technology 83 000 filter set with single band exitors for Texas Red/Rhodamine, FITC and DAPI (UV 360 nm). Only individual and well-delineated cells with two hybridization signals were scored. Overlapping cells were excluded from the analysis. In all 50-100 cells per sample were scored to obtain an average of signals.
SYBR-green real-time quantitation PCR
LightCycler FastStart DNA Master SYBR-Green I kit was used for real-time PCR amplification. The reaction was carried out in a LightCyclert machine (Roche Applied Science, Indianapolis, IN, USA). A quantitation standard curve of normal male DNA from 50 000 to 500 000 copies of genome was generated using known amounts of template copies. Genomic DNA (100 ng) were used for all of the experimental and control samples. HotStarTaq DNA polymerase (Qiagen, Valencia, CA, USA) was activated with a 10 min preincubation step at 951C. MCM7 amplification was performed with 45 cycles of the following program: 941C for 10 s, 621C for 5 s and 721C for 10 s. LightCycler data software version 3.5 was used to quantify and to fit the data with a standard curve. A separate b-actin DNA quantification was also performed in parallel with MCM7 analysis.
Construction of constitutive MCM7-expressing cell lines MCM7 cDNA was obtained by extended long PCR (Roche Applied Science, NJ, USA) using primers (TGATTGGC TTGCGGCTAGCGG/GGAGTAAGTGCAGCATGGGAG) encompassing the coding region on cDNA templates from a donor prostate sample. The procedure of RNA extraction and cDNA synthesis were similar to those described in mRNA oligoarray. The PCR was set as the following condition: 941C for 1 min, then 941C for 15 s, 611C for 2 min and 681C for 8 min for 35 cycles. The 2.4 Kb PCR product was ligated into a TA cloning vector using TOPO TA cloning kit (InVitrogen, CA, USA). Six clones were picked for plasmid DNA analysis. The selected MCM7-containing plasmid was digested with HindIII and XhoI, and the insert was ligated into a similarly digested pCMVscript vector. The final pCMV-MCM7 construct was sequenced (automated sequencing by University of Pittsburgh biotechnology support center) to confirm that no mutations had been introduced into the cDNA. This construct was transfected into DU145 cells, the only cell line with low MCM7 expression, using superfectt kit (Invitrogen, CA, USA). Colonies containing the pCMV-MCM7 construct were selected with minimum essential medium (MEM), 10% fetal bovine serum (FBS) and 400 mg/ml G418. In all, 11 colonies (MD1-MD11) of pCMV-MCM7-transformed cells and 12 clones (PD0-PD11) of pCMVscript-transformed cells were picked.
Immunoblot detection of MCM7
To examine the MCM7 expression, the cells were washed with PBS and lysed by RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40: 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mg/ml each of aprotinin, leupeptin, pepstatin, 1 mM Na 3 VO 4 ). The lysates were sonicated and centrifuged to remove the insoluble materials. The proteins were resolved in SDS-PAGE in 8.5% polyacrylamide gel, and blotted onto PVDF membrane. The membrane was blocked with 5% powdered skim milk in Tris-Tween-20 buffer, pH 7.4, for 1 h in room temperature, followed by 2 h of incubation of primary anti-MCM7 antibodies (Santa Cruz biotechnology, Santa Cruz, CA, USA). The membrane was then washed three times with Tris-Tween-20 buffer and incubated with horseradish peroxidase-conjugated secondary antibody specific for mouse for 1 h at room temperature. The MCM7 expression was detected with the ECL system (Amersham Life Science) according to the manufacturer's protocols.
Cell cycle analysis MD9, MD11, PD0 and PD4 cells were cultured with MEM with 10% FBS and 400 mg/ml G418 at 371C and 5% C0 2 to 40-50% confluence. These cells were treated with MEM medium containing no serum for 24 h to synchronize the culture to G 0 phase. The cultures were then switched to medium with 10% FBS for 6 h. The cells were subsequently harvested and Amplification of MCM7 in prostate cancer B Ren et al centrifuged at 500 g for 5 min, and resuspended in 0.5 ml PBS. The cells were transferred to another tube and held in 4.5 ml 70% cold ethanol for 2 h. The cell pellets were stained in 1 ml propidium iodide/Triton X-100 staining for 30 min at room temperature. The DNA content and cell number was quantified with flow cytometry analysis using a FACSCalibur Automated Benchtop Flow Cytometer (Becton Dickinson, MA, USA). The data were quantified and analysed through Cell Quest program.
Immunohistochemistry and tissue array analysis Formalin-fixed and paraffin-embedded human prostate tissue specimens, including 280 prostate cancer and 181 normal prostate samples from 220 individuals, were arrayed onto slides in a format of single or duplicate representation for each sample. The ages of patients range from 45 to 79.
Complete 5-year follow-up data are available for 155 of the prostrate cancer cases. In all, 40 thin-cut slides from formalin-fixed paraffin-embedded tissue blocks of 40 (29 with clinical follow-up) cases of prostate cancer were also included in the immunohistochemistry analysis. Therefore, the total number of samples processed for immunohistochemistry was 320 (260 individuals). These samples represent part of the archived prostate tissue collection in University of Pittsburgh Medical Center from 1985 to 1999.
Mouse anti-MCM7 monoclonal antibody (Santa Cruz biotechnology, Santa Cruz, CA, USA) was prepared at a 1:1000 dilution. The immunohistochemistry procedure was performed as described previously (Jing et al., 2004) . Immunolabeling specificity was verified by incubating similar slides without a primary antibody. The expression of MCM7 was graded as 0 if no cells within the tumor were stained, 0.5 þ /À if focally positive cells for MCM7 were found, 1 þ if o20% of cells were positive, 2 þ if 20-50% of cells were positive, 3 þ if 50-80% of cells were positive and 4 þ if >80% of cells were positive. The overall score for each sample represents a consensus of scores by three observers who were blinded to the patients' clinical outcomes.
Matrigel transmigration analysis
The procedure of Matrigel transmigration analysis was described previously (Jing et al., 2004) . Briefly, cells from each clone (MD9, MD11, PD0 and PD4) were suspended in DMEM medium containing 0.1% bovine serum albumin added to the upper chamber at a density of 1 Â 10 5 cells/insert. A conditioned medium obtained by incubating NIH 3T3 cells for 24 h in serum-free DMEM in the presence of 50 mg/ml ascorbic acid were placed in the lower compartment of the invasion chambers (Becton-Dickinson, MA, USA) as chemoattractants. After 24 h of culture, the upper surfaces of the inserts were wiped with cotton swabs, for subsequent hematoxylin and eosin (H&E) staining. Each experiment was performed twice with each sample in triplicate. The cells that migrated through the Matrigel and the filter pores to the lower surface were counted under a light microscope with five random high-power fields per insert.
Tumor growth and spontaneous metastasis Severe combined immunodeficient (SCID) mice (Taconic, Germantown, NY, USA) were subcutaneously implanted at the abdominal flank with B1 Â 10 6 viable cells, suspended in 0.2 ml of Hanks' balanced salt solution. The animals were observed daily. Body weight, tumor size and other special findings, including lymph-node enlargement, were recorded weekly. After 6 weeks or when the mice became moribund, they were sacrificed, and autopsies were killed. Serial sections of lung, brain, liver, kidneys, vertebra and lymph nodes were collected. These tissues were formalin-fixed and paraffinembedded. The sections were stained with H&E and subject to histology examination. All animal procedures were approved by the University of Pittsburgh IACUC.
